Targeting Astrocytes Ameliorates Neurologic Changes in a Mouse Targeting Astrocytes Ameliorates Neurologic Changes in a Mouse Model of Alzheimer's Disease Model of Alzheimer's Disease

,

[1]  M. Farlow,et al.  Immunotherapy for Alzheimer's disease. , 2013, Neurologic clinics.

[2]  Janna H. Neltner,et al.  Early Stage Drug Treatment That Normalizes Proinflammatory Cytokine Production Attenuates Synaptic Dysfunction in a Mouse Model That Exhibits Age-Dependent Progression of Alzheimer's Disease-Related Pathology , 2012, The Journal of Neuroscience.

[3]  I. Torres-Aleman,et al.  Regulation of the phosphatase calcineurin by insulin-like growth factor I unveils a key role of astrocytes in Alzheimer's pathology , 2012, Molecular Psychiatry.

[4]  B. Hyman,et al.  Distinct Dendritic Spine and Nuclear Phases of Calcineurin Activation after Exposure to Amyloid-β Revealed by a Novel Fluorescence Resonance Energy Transfer Assay , 2012, The Journal of Neuroscience.

[5]  P. Landfield,et al.  Reduction in neuronal L-type calcium channel activity in a double knock-in mouse model of Alzheimer's disease. , 2012, Biochimica et biophysica acta.

[6]  B. Hyman,et al.  Inhibition of the NFAT Pathway Alleviates Amyloid Beta Neurotoxicity in a Mouse Model of Alzheimer's Disease , 2012, The Journal of Neuroscience.

[7]  Ove Almkvist,et al.  Evidence for Astrocytosis in Prodromal Alzheimer Disease Provided by 11C-Deuterium-L-Deprenyl: A Multitracer PET Paradigm Combining 11C-Pittsburgh Compound B and 18F-FDG , 2012, The Journal of Nuclear Medicine.

[8]  Tara Spires-Jones,et al.  Spines, Plasticity, and Cognition in Alzheimer's Model Mice , 2011, Neural plasticity.

[9]  R. Vassar,et al.  The contribution of activated astrocytes to Aβ production: Implications for Alzheimer's disease pathogenesis , 2011, Journal of Neuroinflammation.

[10]  Hélène Marie,et al.  Hippocampal synaptic plasticity in Alzheimer's disease: what have we learned so far from transgenic models? , 2011, Alzheimer's & Dementia.

[11]  Christopher M Norris,et al.  Preparation of acute hippocampal slices from rats and transgenic mice for the study of synaptic alterations during aging and amyloid pathology. , 2011, Journal of visualized experiments : JoVE.

[12]  Anjana Rao,et al.  Interaction of calcineurin with substrates and targeting proteins. , 2011, Trends in cell biology.

[13]  Inbal Goshen,et al.  Immune modulation of learning, memory, neural plasticity and neurogenesis , 2011, Brain, Behavior, and Immunity.

[14]  C. Norris,et al.  Proteolysis of calcineurin is increased in human hippocampus during mild cognitive impairment and is stimulated by oligomeric Abeta in primary cell culture , 2011, Aging cell.

[15]  Michael Aschner,et al.  Role of Astrocytes in Brain Function and Disease , 2011, Toxicologic pathology.

[16]  E. Mufson,et al.  Bioactivity of AAV2‐neurturin gene therapy (CERE‐120): Differences between Parkinson's disease and nonhuman primate brains , 2011, Movement disorders : official journal of the Movement Disorder Society.

[17]  A. Verkhratsky,et al.  Astrocytes in Alzheimer’s disease , 2010, Neurotherapeutics.

[18]  G. Taglialatela,et al.  Amyloid‐β oligomers impair fear conditioned memory in a calcineurin‐dependent fashion in mice , 2010, Journal of neuroscience research.

[19]  R. Samulski,et al.  Adeno-associated virus for the treatment of muscle diseases: toward clinical trials. , 2010, Current opinion in molecular therapeutics.

[20]  C. Combs,et al.  Microglial Phenotype Is Regulated by Activity of the Transcription Factor, NFAT (Nuclear Factor of Activated T Cells) , 2010, The Journal of Neuroscience.

[21]  A. Verkhratsky,et al.  Early astrocytic atrophy in the entorhinal cortex of a triple transgenic animal model of Alzheimer's disease , 2011, ASN neuro.

[22]  G. Landreth,et al.  The role of microglia in amyloid clearance from the AD brain , 2010, Journal of Neural Transmission.

[23]  A. Ammit,et al.  Targeting p38 MAPK pathway for the treatment of Alzheimer's disease , 2010, Neuropharmacology.

[24]  Tara Spires-Jones,et al.  Amyloid β Induces the Morphological Neurodegenerative Triad of Spine Loss, Dendritic Simplification, and Neuritic Dystrophies through Calcineurin Activation , 2010, The Journal of Neuroscience.

[25]  M. Murphy,et al.  BACE1 and BACE2 enzymatic activities in Alzheimer’s disease , 2010, Journal of neurochemistry.

[26]  E. Blalock,et al.  Hippocampal ‘zipper’ slice studies reveal a necessary role for calcineurin in the increased activity of L-type Ca2+ channels with aging , 2010, Neurobiology of Aging.

[27]  C. Norris,et al.  Disparate effects of serum on basal and evoked NFAT activity in primary astrocyte cultures , 2010, Neuroscience Letters.

[28]  S. Scheff,et al.  Recovery of afferent function and synaptic strength in hippocampal CA1 following traumatic brain injury. , 2009, Journal of neurotrauma.

[29]  M. Sofroniew,et al.  Astrocytes: biology and pathology , 2009, Acta Neuropathologica.

[30]  M. Sofroniew.  Molecular dissection of reactive astrogliosis and glial scar formation , 2009, Trends in Neurosciences.

[31]  G. Münch,et al.  Activated astrocytes: a therapeutic target in Alzheimer’s disease? , 2009, Expert review of neurotherapeutics.

[32]  H. Abdul,et al.  Cognitive Decline in Alzheimer's Disease Is Associated with Selective Changes in Calcineurin/NFAT Signaling , 2009, The Journal of Neuroscience.

[33]  I. Mook‐Jung,et al.  RAGE regulates BACE1 and Aβ generation via NFAT1 activation in Alzheimer's disease animal model , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  Jose Julio Rodriguez,et al.  Astroglia in dementia and Alzheimer's disease , 2009, Cell Death and Differentiation.

[35]  D. Butterfield,et al.  Proteomics-determined differences in the concanavalin-A-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer's disease and mild cognitive impairment: implications for progression of AD. , 2009, Journal of proteome research.

[36]  G. Taglialatela,et al.  Selective induction of calcineurin activity and signaling by oligomeric amyloid beta , 2008, Aging cell.

[37]  Christopher M Norris,et al.  Interleukin-1β-dependent Signaling between Astrocytes and Neurons Depends Critically on Astrocytic Calcineurin/NFAT Activity* , 2008, Journal of Biological Chemistry.

[38]  P. Calabresi,et al.  Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. , 2008, Trends in pharmacological sciences.

[39]  J. Redondo,et al.  Calcium/calcineurin signaling in primary cortical astrocyte cultures: Rcan1‐4 and cyclooxygenase‐2 as NFAT target genes , 2008, Glia.

[40]  P. Agostinho,et al.  Overactivation of calcineurin induced by amyloid-beta and prion proteins , 2008, Neurochemistry International.

[41]  I. Mook‐Jung,et al.  Disrupted intracellular calcium regulates BACE1 gene expression via nuclear factor of activated T cells 1 (NFAT 1) signaling , 2008, Aging cell.

[42]  Michael Brenner,et al.  GFAP promoter elements required for region‐specific and astrocyte‐specific expression , 2008, Glia.

[43]  R. A. Wallis,et al.  Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. , 2008, Brain : a journal of neurology.

[44]  S. Skaper.  The Brain as a Target for Inflammatory Processes and Neuroprotective Strategies , 2007, Annals of the New York Academy of Sciences.

[45]  R. Anwyl,et al.  Synaptic memory mechanisms: Alzheimer's disease amyloid beta-peptide-induced dysfunction. , 2007, Biochemical Society transactions.

[46]  I. Torres-Aleman,et al.  Calcineurin in Reactive Astrocytes Plays a Key Role in the Interplay between Proinflammatory and Anti-Inflammatory Signals , 2007, The Journal of Neuroscience.

[47]  David Eidelberg,et al.  Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial , 2007, The Lancet.

[48]  M. O’Banion,et al.  Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. , 2007, The Journal of clinical investigation.

[49]  C. Cotman,et al.  Beta-amyloid causes downregulation of calcineurin in neurons through induction of oxidative stress , 2007, Neurobiology of Disease.

[50]  R. Berry,et al.  β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Levels Become Elevated in Neurons around Amyloid Plaques: Implications for Alzheimer's Disease Pathogenesis , 2007, The Journal of Neuroscience.

[51]  Bernardo L Sabatini,et al.  Natural Oligomers of the Alzheimer Amyloid-β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway , 2007, The Journal of Neuroscience.

[52]  M. Ohno,et al.  Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation , 2006, The Journal of Neuroscience.

[53]  T. Klockgether,et al.  Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms , 2006, International Journal of Developmental Neuroscience.

[54]  D. Bennett,et al.  Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment , 2006, Neurobiology of Aging.

[55]  H. Cai,et al.  BACE1, a Major Determinant of Selective Vulnerability of the Brain to Amyloid-β Amyloidogenesis, is Essential for Cognitive, Emotional, and Synaptic Functions , 2005, The Journal of Neuroscience.

[56]  K. Tomizawa,et al.  Truncation and Activation of Calcineurin A by Calpain I in Alzheimer Disease Brain* , 2005, Journal of Biological Chemistry.

[57]  J. Hardy,et al.  Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice , 2005, Neuron.

[58]  E. Blalock,et al.  Calcineurin Triggers Reactive/Inflammatory Processes in Astrocytes and Is Upregulated in Aging and Alzheimer's Models , 2005, The Journal of Neuroscience.

[59]  H. Arias,et al.  The role of inflammation in Alzheimer's disease. , 2005, The international journal of biochemistry & cell biology.

[60]  A. Rao,et al.  Activation and deactivation of gene expression by Ca2+/calcineurin-NFAT-mediated signaling. , 2004, Molecules and cells.

[61]  M. Mattson.  Pathways towards and away from Alzheimer's disease , 2004, Nature.

[62]  R. Malenka.  The long-term potential of LTP , 2003, Nature Reviews Neuroscience.

[63]  Thomas Klockgether,et al.  Nonsteroidal Anti-Inflammatory Drugs and Peroxisome Proliferator-Activated Receptor-γ Agonists Modulate Immunostimulated Processing of Amyloid Precursor Protein through Regulation of β-Secretase , 2003, The Journal of Neuroscience.

[64]  G. Crabtree,et al.  NFAT Signaling Choreographing the Social Lives of Cells , 2002, Cell.

[65]  Valerie Horsley,et al.  NFAT: ubiquitous regulator of cell differentiation and adaptation. , 2002, The Journal of cell biology.

[66]  V. Bigl,et al.  Neuronal and glial β‐secretase (BACE) protein expression in transgenic Tg2576 mice with amyloid plaque pathology , 2001, Journal of neuroscience research.

[67]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[68]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[69]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[70]  M. Yaffe,et al.  Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. , 1999, Science.

[71]  T. Foster,et al.  Reversal of Age-Related Alterations in Synaptic Plasticity by Blockade of L-Type Ca2+ Channels , 1998, The Journal of Neuroscience.

[72]  B. Hyman,et al.  Edinburgh Research Explorer Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation , 2018 .

[73]  J. Bennett,et al.  Adeno-associated virus mediated gene therapy for retinal degenerative diseases. , 2011, Methods in molecular biology.

[74]  Stephen W. Scheff,et al.  Mild cognitive impairment: pathology and mechanisms , 2011, Acta Neuropathologica.

[75]  S. Son,et al.  FK506 reduces amyloid plaque burden and induces MMP-9 in AβPP/PS1 double transgenic mice. , 2010, Journal of Alzheimer's disease : JAD.

[76]  D. Small,et al.  Astrocytes in Alzheimer's disease: emerging roles in calcium dysregulation and synaptic plasticity. , 2010, Journal of Alzheimer's disease : JAD.

[77]  Mak Adam Daulatzai,et al.  Early stages of pathogenesis in memory impairment during normal senescence and Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[78]  L. V. Van Eldik,et al.  Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches. , 2007, International review of neurobiology.

[79]  W. Markesbery,et al.  Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. , 2007, Neurobiology of disease.

[80]  D. Borchelt,et al.  Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. , 2004, Human molecular genetics.

[81]  T. Foster.  Regulation of synaptic plasticity in memory and memory decline with aging. , 2002, Progress in brain research.

[82]  T. Foster,et al.  Age-associated changes in Ca(2+)-dependent processes: relation to hippocampal synaptic plasticity. , 1997, Hippocampus.

[83]  José Luis Fernández,et al.  Authors! Authors! , 1991, Science.